StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Investment analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of EGRX stock opened at $0.88 on Friday. The stock’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $1.17. Eagle Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $6.37.

Institutional Trading of Eagle Pharmaceuticals

Large investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. bought a new stake in Eagle Pharmaceuticals during the third quarter valued at about $453,000. RBF Capital LLC lifted its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares during the last quarter. Jane Street Group LLC bought a new stake in Eagle Pharmaceuticals during the 3rd quarter valued at approximately $96,000. Finally, DGS Capital Management LLC grew its holdings in Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares during the last quarter. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.